Background: Tacrolimus is a potent immunosuppressive drug used in organ transplantation. Because of its substantial toxic effects, narrow therapeutic index, and interindividual pharmacokinetic variability, therapeutic drug monitoring of whole-blood tacrolimus concentrations has been recommended. We investigated the comparability of the results of 2 immunoassay systems, affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA), comparing differences in the tacrolimus concentrations measured by the 2 methods in relation to the hematologic and biochemical values of hepatic and renal functions.
Methods: A total of 154 samples from kidney or liver transplant recipients were subjected to Dimension RxL HM with a tacrolimus Flex reagent cartilage for the ACMIA method and IMx tacrolimus II for the MEIA method.
Results: Tacrolimus concentrations measured by the ACMIA method (n = 154) closely correlated with those measured by the MEIA method (r = 0.84). The Bland-Altman plot using concentration differences between the 2 methods and the average of the 2 methods showed no specific trends. The tacrolimus levels determined by both the MEIA method and the ACMIA method were not influenced by hematocrit levels, but the difference between the 2 methods (ACMIA - MEIA) tended to be larger in low hematocrit samples (P < .001).
Conclusion: The ACMIA method used for a tacrolimus assay is precise and has advantages, including the lack of a required pretreatment procedure. Furthermore, it is only slightly influenced by the hematologic or biochemical status of the samples.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2008.04.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lack of Interchangeability Between 3 Different Methods for Quantification of Everolimus in Blood: ACMIA, LTIA, and UHPLC-MS/MS.
Ther Drug Monit
July 2024
Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
Background: Affinity chrome-mediated immunoassays (ACMIA) do not require pretreatment and have a wide calibration range and good analytical performance. To date, no studies have compared ACMIA and latex agglutination turbidimetry immunoassays (LTIA). The objective of this study was to evaluate the interchangeability of ACMIA, LTIA, and the previously developed ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS).
View Article and Find Full Text PDFValidation of an automated sample preparation module directly connected to LC-MS/MS (CLAM-LC-MS/MS system) and comparison with conventional immunoassays for quantitation of tacrolimus and cyclosporin A in a clinical setting.
J Pharm Health Care Sci
January 2024
Department of Clinical Pharmacokinetics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
Article Synopsis
- The study aimed to assess the effectiveness of a new CLAM-LC-MS/MS system for monitoring levels of immunosuppressive drugs (tacrolimus and cyclosporin A) in whole blood, addressing the drawbacks of existing methods like liquid chromatography and immunoassays.
- Researchers validated this system using blood samples from patients at Kanazawa University Hospital, comparing results from the CLAM-LC-MS/MS with commercial immunoassay techniques.
- The findings revealed strong correlations between the two methods, although CLAM-LC-MS/MS showed approximately 20% lower drug concentrations; the system also improved efficiency in drug measurement compared to traditional manual pretreatment processes.
Puzzling interference in the Siemens tacrolimus assay in a renal transplant patient: A case report.
Clin Chim Acta
March 2023
Department of Laboratory Medicine, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain. Electronic address:
Background: Therapeutic drug monitoring is a key tool for optimizing tacrolimus therapy in transplant recipients. The modified ACMIA assay from Siemens Healthcare Diagnostics is an immunoassay commonly used for tacrolimus monitoring, but it is not known whether this assay is resistant to interference from endogenous substances in real-world use.
Objective: To describe a case of unexpected interference in tacrolimus monitoring using the modified ACMIA method in a kidney transplant recipient, and to highlight the importance of careful interpretation of laboratory results and effective communication with clinicians in optimizing patient care.
Analytical Performance of the New Siemens Affinity Chrome-Mediated Immunoassay Everolimus Assay and Its Interchangeability With the Thermo Quantitative Microsphere System for Routine Therapeutic Drug Monitoring of Patients After Solid Organ Transplantation.
Ther Drug Monit
April 2023
Department of Experimental Medicine, Policlinico Umberto I, "Sapienza" University, Rome, Italy.
Background: A new homogeneous affinity chrome-mediated immunoassay (ACMIA) "EVRO" from Siemens Healthcare was evaluated for therapeutic drug monitoring of everolimus (EVL) with automated sample pretreatment and compared with quantitative microsphere system (QMS) "EVER" from Thermo Fisher Scientific.
Methods: Imprecision, inaccuracy, and limit of quantitation (LoQ) of ACMIA/EVRO were verified using both hemolysate quality control (QC) samples and pooled whole blood specimens. The interchangeability of methods and the agreement of results were analyzed using 72 specimens (from 38, 30, and 4 kidney, liver, and lung transplant recipients, respectively).
Evaluation of the interchangeability between the new fully-automated affinity chrome-mediated immunoassay (ACMIA) and the Quantitative Microsphere System (QMS) with a CE-IVD-certified LC-MS/MS assay for therapeutic drug monitoring of everolimus after solid organ transplantation.
Clin Chem Lab Med
January 2023
Clinical Biochemistry Laboratory, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
Objectives: This study aims to evaluate the interchangeability between the Siemens Healthineers' "EVRO" new affinity chrome-mediated immunoassay (ACMIA/EVRO) and Thermo Fisher Scientific's "EVER" Quantitative Microsphere System (QMS/EVER) with Chromsystems' CE-IVD-certified "MassTox" liquid-chromatography/tandem-mass spectrometry (LC-MS/MS) assay for the therapeutic drug monitoring of everolimus.
Methods: A single lot of reagent, calibrators and controls were used for each assay. A total of 67 whole blood samples (n=67) from patients receiving solid organ transplant were analyzed (n=31 with kidney transplant and n=36 with liver transplant); Passing-Bablok regression and Bland-Altman difference plot were used to evaluate bias and individual agreement; LC-MS/MS analysis was used to measure the actual concentrations of calibrators and controls compared to the assigned value.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!